EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Utilizing Virtual Clinical Trials to Inform Target Coverage That Drives RSV Antiviral Efficacy

J Cody Herron iD, Kathryn G Link iD, Natalie Meacham, Negar Niki Alami iD, Daniel W Brookes iD, Elaine Thomas iD, Jan Adams, Sima S Toussi, Ryan Franke, Cynthia J Musante iD, Isabel Najera, Richard Allen iD und 1 weitere

CPT: Pharmacometrics & Systems Pharmacology · 2026-08 · 15 (8)

DOI: 10.1002/psp4.70308 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, online erschienen am 31.07.2026. Verfasst von J Cody Herron und 12 weiteren Autor:innen. Beteiligte Einrichtung: Pfizer Inc., Translational Clinical Sciences, Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: Antiviral Agents, Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus, Human. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Respiratory syncytial virus (RSV) infection can result in a range of disease severity from mild upper respiratory tract symptoms to lower respiratory tract illness, with clinical manifestations dependent on age, co‐morbidities, and immune status. At present, there is no antiviral approved for adults with RSV disease, and only one treatment option with limited utilization is available for pediatric patients. While several RSV antiviral candidates have demonstrated virological efficacy in healthy adult challenge studies, to date they have subsequently failed to show efficacy in patients. Mechanistically understanding the translation of efficacy from preclinical to challenge to patient studies is essential in addressing this unmet medical need in children and adults with RSV disease. This work uses a quantitative systems pharmacology (QSP) approach to mathematically represent the underlying pathophysiology of RSV infection to simulate and predict the effects of investigational direct acting RSV antiviral therapeutics. We developed virtual populations that capture viral load dynamics in viral challenge studies, where the participants are healthy adult volunteers, upon treatment with the F‐protein inhibitor sisunatovir and the N‐protein inhibitor zelicapavir. Due to underlying differences in dynamics between key populations, we also developed a pediatric patient virtual population to match the results from the zelicapavir pediatric Phase 2 study. This work projects that for a minimum coverage > 1× free EC 90 at C min , a treatment window of 5 to 7 days post‐symptom onset is feasible for observing virological efficacy in pediatric patients and may lead to potential success in a phase 3 pivotal RSV antiviral drug trial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsRespiratory Syncytial Virus InfectionsRespiratory Syncytial Virus, HumanHumansViral LoadAdultSulfonamidesClinical Trials as TopicChild

Stichwörter der Autor:innen

antiviral therapyquantitative systems pharmacologyrespiratory syncytial virusviral dynamics modelingvirtual populations

Substanzen

Antiviral AgentsSulfonamides

Autor:innen und Institutionen

  • Pfizer Inc., Translational Clinical Sciences, Cambridge, Massachusetts, USA.
  • Pfizer Inc., R&D, Pearl River, New York, USA.
  • Pfizer Inc., R&D, UK, London, UK.
  • Pfizer Inc., Preclinical & Translational Sciences, La Jolla, California, USA.

ORCID-Profile: J Cody Herron, Kathryn G Link, Negar Niki Alami, Daniel W Brookes, Elaine Thomas, Cynthia J Musante, Richard Allen, Britton Boras

Zitieren

APA

Herron, J. C., Link, K. G., Meacham, N., Alami, N. N., Brookes, D. W., Thomas, E., Adams, J., Toussi, S. S., Franke, R., Musante, C. J., Najera, I., Allen, R., & Boras, B. (2026). Utilizing Virtual Clinical Trials to Inform Target Coverage That Drives RSV Antiviral Efficacy. CPT: Pharmacometrics & Systems Pharmacology, 15(8). https://doi.org/10.1002/psp4.70308

Vancouver

Herron JC, Link KG, Meacham N, Alami NN, Brookes DW, Thomas E, et al. Utilizing Virtual Clinical Trials to Inform Target Coverage That Drives RSV Antiviral Efficacy. CPT: Pharmacometrics & Systems Pharmacology. 2026;15(8). doi:10.1002/psp4.70308

BibTeX
@article{Herron2026,
  author = {Herron, J Cody and Link, Kathryn G and Meacham, Natalie and Alami, Negar Niki and Brookes, Daniel W and Thomas, Elaine and Adams, Jan and Toussi, Sima S and Franke, Ryan and Musante, Cynthia J and Najera, Isabel and Allen, Richard and Boras, Britton},
  title = {Utilizing Virtual Clinical Trials to Inform Target Coverage That Drives RSV Antiviral Efficacy},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2026},
  volume = {15},
  number = {8},
  doi = {10.1002/psp4.70308}
}
Kostenlos starten →